

POLAND

Recent and planned developments in pharmaceutical policies 2014

Policies related to high cost medicines

D E V E L O P M E N T S	Changes in pricing	Changes in reimbursement
	<p><i>Polish MoH tries to initiate international discussion about fair pricing.</i></p>	<ul style="list-style-type: none"> • <i>In POLAND ICUR for new INN can't exceed 3xGDP. From 5th October its value is 119 577 PLN/QALY (approx. 28 336 EUR/QALY).</i> • <i>From 11th September doctors can prescribe the chronically used medicines for one year (e.g. drugs for hypertension).</i>
S P E C I A L T O P I C	Other changes	
	<ul style="list-style-type: none"> • <i>AHTAPol in published documents (HTA analysis and its verification) will be circled only the sections on risk-sharing instruments, the price and nowhere unpublished research results. Explicit will be data on the safety of the medicine, information about reimbursement in other countries, the results of clinical trials, the ICUR or ICER indicators, information on clinical efficacy and practical information obtained health effects, information on adverse effects, the available scientific evidence, the impact on the budget public payer.</i> • <i>From 1st January 2015 AHTAPol will be set the price for hospitals procedures. These values will be used by the NHF to sign contracts with hospitals.</i> • <i>The possibility of obtaining a prescription for medication to continue without a personal visit to the doctor. Any doctor who knows the patient's condition and has his medical records, will be able to continue treatment, writing out a prescription for the drug to the patient - no need to notify the patient's visit. The patient will not have to wait in line just to get another prescription.</i> • <i>Implementation of waiting lists. The patient will check on the NHF website how long is the waiting list.</i> • <i>Financial limits abolition in the treatment of oncology - hospitals should not send patients because of exceeding the limit of the contract with the NHF. The creation of fast track diagnostic and therapeutic for patients with suspected cancer.</i> • <i>Oncology card - a document owned by the patient and containing all the information about its treatment. The patient with the card will be prioritized by the medical facility. After the treatment the information will be transferred to the card, which will enable GP to access to the information of full previous treatment.</i> 	
High cost medicines		
<ul style="list-style-type: none"> • <u>Special pricing policies:</u> There are no specific pricing policies for high cost medicines. We refuse reimbursement of Sofosbuvir. • <u>Special reimbursement/funding policies:</u> There are no specific pricing policies for high cost medicines. In Poland registration status (orphan drugs) does not translate to the specific conditions of reimbursement. • <u>High cost medicines at the interface of out-patient and in-patient sectors:</u> Dual financing for all medicines in Poland: In the out-patient sector: medicines included in the reimbursement list are reimbursed by the national health fund. They are sold in pharmacies with 0 PLN or fixed charge to the financed limit. In the in-patient sector: all medicines are free of charge for patients (including those not included in the list of reimbursed drugs). For specific medicines, there are risk sharing agreements. Most of them are available in drugs programme. • <u>Key challenges and solutions:</u> 		